COI Centro Oncologico Internacional S.A.P.I. de C.V.

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer4 trials
• Cervical cancer1 trial
• Colorectal cancer1 trial
• Lung cancer1 trial
• Prostate cancer1 trial
• Sarcoma1 trial

Phase

• Phase 23 trials
• Phase 32 trials

Status

• Active, not recruiting3 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Pfizer3 trials
• Agenus Inc.1 trial
• Gilead Sciences1 trial

Running trials

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Pfizer· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

  NCT05840211· Phase 3· Gilead Sciences· Source

• Recruiting

  Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

  NCT04557449· Phase 2· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer1 recruiting

Closed trials

• Terminated

  RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

  NCT03894215· Phase 2· Agenus Inc.· Source